吉非替尼与厄罗替尼治疗晚期非小细胞肺癌的临床分析-肿瘤学专业论文.docxVIP

— — PAGE 1— 摘 要 吉非替尼与厄罗替尼治疗晚期 非小细胞肺癌的临床分析 研究生：王治华 导师：唐勇 副教授 摘 要 目的：吉非替尼与厄罗替尼是一种表皮生长因子受体酪氨酸激酶的选择性抑制 剂,临床常用于治疗晚期非小细胞肺癌，本文回顾性分析了吉非替尼与厄罗替尼治疗 晚期(ⅢB/Ⅳ期)非小细胞肺癌的疗效、不良反应及两药疗效和副反应对比。方法：58 例中晚期非小细胞肺癌患者，分为吉非替尼方案组(A 组)33 例，空腹口服吉非替尼 250mg/日，厄罗替尼方案组(B 组)25 例，空腹口服厄罗替尼 150mg/日，两组均 30 天 为一周期，均在用药 1 个周期后进行疗效评价。直到疾病进展或因毒副作用不能耐 受而终止治疗为止。结果：A 组有效率 27.3%，疾病控制率为 45.5%，B 组有效率 44%， 疾病控制率为 60%，二者差异无统计学意义(P0.05)；A 组中位无疾病进展时间为 4.5 个月，B 组为 5.0 个月，二者差异无统计学意义(P0.05)；A 组中位生存时间为 9.0 个月 B 组为 8.0 个月二者差异无统计学意义(P0.05)；两者毒副反应主要为Ⅰ～Ⅱ皮 疹与腹泻，其中 A 组为 57.6%与 18.2%，B 组为 64%与 12%，两者差异无统计学意 义 (P0.05)，结论：尚不能认为吉非替尼与厄罗替尼方案治疗中晚期非小细胞肺癌 的疗效有差别，两药对于晚期非小细胞肺癌均有较好的疗效与安全性 关键词：非小细胞肺癌；吉非替尼；厄罗替尼；靶向治疗 新疆医科大学医学硕士学位论文 Clinical Observation of Gefitinib and Eelotinib in Treatment with Non-small Cell Lung Cancer Postgraduate: Wang Zhihua Tutor:Tang Yong Vice Professor Abstract Objective: Gefitinib and Eelotinib are sort of selectivity inhibitor of epidermal growth factor receptors（EGFR）tyrosine kinase, ,and are used in treating advanced non-small cell lung cancer（. NSCLC）。This study is to review and evaluate the efficacy of Gefitinib and Eelotinib on advanced NSCLC，and observe the adverse events .Methods: A total of 58 patients with advanced non-small cell lung cancer were divided into the Gefitinib group (group A n=33) and Eelotinib group (group B n=25). In group A, Gefitinib(250 mg ) was orally administrated daily. In group B, Eelotinib (150 mg ) was orally administrated daily. till disease progression or intolerable adverse events developed .Results: In group A,the objective response rate was 27.3%,and the disease control rate was 45.5%; In group B,the objective response rate was 44%,and the disease control rate was 60%；there was no significant difference between the two groups in curative effect （P0.05）.In group A, the median progression free survival time was 4.5 months,and the median survival time was 9.0 months；In group B, the median progression free survival time was 5.0 months,and the median survival time was 8